Santen reports positive top-line data from SAKURA programme of OPSIRIA to treat uveitis

Japanese specialty ophthalmology company Santen Pharmaceutical has reported positive topline results from its SAKURA clinical development programme of OPSIRIA (440 µ g sirolimus injection) to treat non-infectious uveitis.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news